Stephanie K. Ladner

TL;DR: The development and isolation of a cell line that replicates human hepatitis B virus under conditions that can be regulated with tetracycline is reported, and this cell line has been formatted into a high-throughput, cell-based assay that permits the large-scale screening of diverse compound libraries for new classes of inhibitors of HBV replication.

TL;DR: The antiviral activity of AT-61 is specific for HBV replication and most likely occurs at one of the steps between the synthesis of viral RNA and the packaging of pregenomic RNA into immature core particles.

TL;DR: A non-nucleoside class of compounds that inhibits the replication of hepatitis B virus in cell culture has been discovered and structure-activity relationships of this series of substituted analogues of phenylpropenamide 6 are discussed.

TL;DR: A plasmid that contained a cDNA copy of the HBV pregenomic RNA was mutated such that when virus replication occurred during transient transfection of HepG2 cells, an M539V polymerase variant was produced and it was found that in transiently transfected cells, this variant was approximately 330-fold less sensitive to the antiviral effects of 3TC.

TL;DR: A non-nucleoside class of compounds that inhibit the replication of hepatitis B virus (HBV) in cell culture has been discovered as discussed by the authors, and a series of substituted analogues of phenylpropenamide Figure 2, Scheme 1 has been prepared and evaluated in the HepAD38 cellular assay.